Skip to main content
Equibles
RGNX logo

RGNX · REGENXBIO Inc. · Earnings Call Transcripts & Audio

Track RGNX — free

Use RGNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RGNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.53 +0.08 (+1.07%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing no longer states the doubt (first flagged May 14, 2026).

View the 10-Q filed Aug 6, 2026
Market Cap
$488.50M
Shares
66.01M
Volume · Sep 30 1.79M Avg daily vol (3M) 1.66M

REGENXBIO Inc. Earnings Call Transcripts

Quarterly earnings calls for REGENXBIO Inc. (RGNX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼13.8% $26.51M −$75.48M '22 Q3 22-11-03 ▼92.1% $31.34M −$59.94M '22 Q4 23-02-28 ▼13.9% $19.14M −$66.68M '23 Q1 23-05-03 ▼38.8% $19.98M −$72.06M '23 Q2 23-08-02 ▲9.1% $28.91M −$61.87M '23 Q3 23-11-08 ▼29.1% $22.21M −$62.89M '23 Q4 24-02-27 ▼18.4% $15.62M −$63.33M '24 Q1 24-05-08 ▲11.6% $22.30M −$52.99M '24 Q2 24-08-01 ▼16.3% $24.20M −$59.60M '24 Q3 24-11-06 ▼4.5% $21.21M −$51.19M '24 Q4 25-03-13 ▲469.8% $89.01M $6.08M '25 Q1 25-05-12 ▼4.2% $21.36M −$70.87M '25 Q2 25-08-07 ▲22.9% $29.73M −$61.94M '25 Q3 25-11-06 ▲43% $30.34M −$67.15M '25 Q4 26-03-05 ▼92.8% $6.39M −$90.05M '26 Q1 26-05-14 LATEST ▲405.7% $108.02M $22.71M '26 Q2 26-08-06
Conference
Investor event
2026-09-16
REGENXBIO Inc. (RGNX) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
REGENXBIO Inc. (RGNX) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript
Confident tone RGX-202 Duchenne gene therapy program ABBVIE / Curovec retinal collaboration RGX-121 Hunter syndrome regulatory progress
Revenue
$108.02M
▲ 405.7% YoY
Diluted EPS
$0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript
Confident tone RGX-202 pivotal Phase III data Microdystrophin expression and functional correlation Approval pathway and regulatory strategy
Revenue
$6.39M
▼ 92.8% YoY
Diluted EPS
$-1.72
▼ 1533.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
Positive tone RGX202 Duchenne gene therapy AbbVie partnership and Navigate in diabetic retinopathy Regulatory pathway and FDA engagement
Revenue
$30.34M*
▲ 43% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript
Confident tone RGX-202 Duchenne pivotal trial and BLA Subretinal sura-vec for wet AMD (AbbVie) RGX-121 MPS II BLA and approval
Revenue
$29.73M
▲ 22.9% YoY
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call
Revenue
$21.36M
▼ 4.2% YoY
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript
Confident tone RGX-202 Duchenne Pivotal Program Retinal Programs / ABBV-RGX-314 Partnership RGX-121 / Hunter Syndrome Regulatory Progress
Revenue
$89.01M
▲ 469.8% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript
Confident tone RGX-202 Duchenne muscular dystrophy pivotal program Regulatory milestones and FDA interactions Clinical data readouts (biomarker and functional)
Revenue
$21.21M*
▼ 4.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Confident tone RGX-202 Duchenne program RGX-314 retinal franchise with AbbVie RGX-121 MPS II / Hunter syndrome BLA
Revenue
$24.20M
▼ 16.3% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript
Confident tone AbbVie RGX-314 retinal programs RGX-202 Duchenne gene therapy Fellow Eye study and immune response
Revenue
$22.30M
▲ 11.6% YoY
Diluted EPS
$-1.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
Confident tone RGX-202 Duchenne program and pivotal dose Diabetic retinopathy suprachoroidal pivotal plans RGX-314 AbbVie collaboration
Revenue
$15.62M
▼ 18.4% YoY
Diluted EPS
$-1.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript
Confident tone RGX-202 Duchenne Program AbbVie Partnership Milestones RGX-121 / MPS II (Hunter Syndrome)
Revenue
$22.21M*
▼ 29.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
REGENXBIO Inc. (RGNX) Q3 2023 Earnings Call Transcript
Revenue
$28.91M
▲ 9.1% YoY
Diluted EPS
$-1.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
REGENXBIO Inc. (RGNX) Q2 2023 Earnings Call Transcript
Revenue
$19.98M
▼ 38.8% YoY
Diluted EPS
$-1.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
REGENXBIO Inc. (RGNX) Q1 2023 Earnings Call Transcript
Revenue
$19.14M
▼ 13.9% YoY
Diluted EPS
$-1.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
REGENXBIO Inc. (RGNX) Q4 2022 Earnings Call Transcript
Revenue
$31.34M*
▼ 92.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
REGENXBIO Inc. (RGNX) Q3 2022 Earnings Call Transcript
Revenue
$26.51M
▼ 13.8% YoY
Diluted EPS
$-1.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
REGENXBIO Inc. (RGNX) Q2 2022 Earnings Call Transcript
Revenue
$32.65M
▲ 48.2% YoY
Diluted EPS
$-1.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
REGENXBIO Inc. (RGNX) Q1 2022 Earnings Call Transcript
Revenue
$22.22M
▲ 17.7% YoY
Diluted EPS
$-1.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
REGENXBIO Inc. (RGNX) Q4 2021 Earnings Call Transcript
Revenue
$398.65M*
▲ 1759% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
REGENXBIO Inc. (RGNX) Q3 2021 Earnings Call Transcript
Revenue
$30.77M
▼ 68.9% YoY
Diluted EPS
$-1.37
▼ 695.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
REGENXBIO Inc. (RGNX) Q2 2021 Earnings Call Transcript
Revenue
$22.04M
▲ 33% YoY
Diluted EPS
$-1.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
REGENXBIO Inc. (RGNX) Q1 2021 Earnings Call Transcript
Revenue
$18.88M
▲ 7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-05
REGENXBIO Inc. (RGNX) Q4 2020 Earnings Call Transcript
Revenue
$21.45M
▲ 82.2% YoY
Diluted EPS
$-1.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
REGENXBIO Inc. (RGNX) Q3 2020 Earnings Call Transcript
Revenue
$98.91M
▲ 572.9% YoY
Diluted EPS
$0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
REGENXBIO Inc. (RGNX) Q2 2020 Earnings Call Transcript
Revenue
$16.57M
▲ 110.2% YoY
Diluted EPS
$-0.91
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
REGENXBIO Inc. (RGNX) Q1 2020 Earnings Call Transcript
Revenue
$17.64M
▲ 1895.9% YoY
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–28 of 28 earnings calls
Key facts CIK 1590877 CUSIP 75901B107 13F (30d) 5 filings 5 filers Visit website Investor relations